{"ModuleTitle": "Company Description", "CompanyName": "VIVUS, Inc.", "Symbol": "VVUS", "Address": "900 E. HAMILTON AVENUE SUITE 550, CAMPBELL, California, 95008, United States of America", "Phone": "6509345200", "Industry": "Major Pharmaceuticals", "Sector": "Health Care", "Region": "North America", "CompanyDescription": "VIVUS is a specialty pharmaceutical company with three approved therapies and\r\none product candidate in clinical development. Qsymia\u00ae (phentermine and\r\ntopiramate extended release) is approved by FDA for chronic weight management.\r\nWe commercialize Qsymia in the U.S. through a specialty sales force supported by\r\nan internal commercial team and license the commercial rights to Qsymia in South\r\nKorea.  In June 2018, we acquired the U.S. and Canadian commercial rights for\r\nPANCREAZE\u00ae/ PANCREASE\u00ae MT (pancrelipase), which is indicated for the treatment\r\nof exocrine pancreatic insufficiency (\"EPI\") due to cystic fibrosis or other\r\nconditions. We commercialize PANCREAZE in the U.S. through a specialty sales\r\nforce supported by an internal commercial team. STENDRA\u00ae (avanafil) is approved\r\nby FDA for erectile dysfunction (\"ED\") and by the European Commission (\"EC\")\r\nunder the trade name SPEDRA, for the treatment of ED in the EU.&nbsp;&nbsp;... <a href=\"http://secfilings.nasdaq.com/edgar_conv_html%2f2020%2f03%2f03%2f0001558370-20-001956.html#FIS_BUSINESS\" target=\"_blank\">More</a> ...&nbsp;&nbsp;\r\n", "KeyExecutives": [{"name": "John P. Amos", "title": "Chief Executive Officer & Director"}, {"name": "Mark K. Oki", "title": "Chief Financial & Accounting Officer, Senior VP"}, {"name": "Santosh T. Varghese", "title": "Chief Medical Officer & Senior Vice President"}], "Number_of_employees": ["NO INFO"], "Subsidiaries": ["NO INFO"]}